Furthermore, RNF43 mutational status is an indicator of sensitivity to Wnt pathway inhibitors (Jiang et al. 2013) and these mutations may thus be useful in predicting therapeutic response for pancreatic cancers which may arise from IPMN precursor lesions. This evidence concerns the gene RNF43 and pancreatic intraductal papillary-mucinous neoplasm.